Veradermics (MANE)
Develops extended-release oral minoxidil for male and female pattern hair loss.
Something off on this page? Send us feedback.
Develops VDPHL01, an extended-release oral minoxidil tablet in late-stage U.S. trials for male and female pattern hair loss, while three earlier dermatology programs remain paused. With no approved products or product-sales revenue, the business depends primarily on FDA approval and commercialization of VDPHL01.
Develops dermatology drugs, led by VDPHL01, a proprietary extended-release oral minoxidil tablet for pattern hair loss in men and women. The U.S.-focused registration program spans two fully enrolled male trials and a fully enrolled female trial; company-announced topline results have been positive in an initial male study and an open-label female study.
Earlier-stage candidates cover common warts (VDMN), alopecia areata (VDAA), and molluscum contagiosum (VDMC), though work on these programs is paused while resources concentrate on VDPHL01. Clinical development combines dermatologist-led indication selection with outsourced trial and manufacturing partners.
Has no approved products or product-sales revenue. Commercial prospects primarily depend on completing registration studies, securing FDA approval for VDPHL01, building sales capabilities, and maintaining supply from third-party manufacturers; one contract manufacturer currently supplies the drug product.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Jul 15, 2026 | B. Riley | Initiate | Buy | ||
| Jul 15, 2026 | UBS | Target | $170 | ||
| Jul 7, 2026 | Jefferies | Reiterate | Buy | $75 | $182 |
| Jun 2, 2026 | Needham | Target | $136 | ||
| Mar 2, 2026 | Jefferies | Target | $75 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $819.9M · Total debt $428.0K · Total assets $825.7M · Shareholders' equity $813.6M
- Revenue
- $0
- Operating income
- −$29.6M
- Net income
- −$23.5M
No dividends on record.
| Institutions166 holders · as of Jun 30, 2026 | 89.09% | 37.22M shares | |
| Otherremainder | 10.91% | 4.56M shares |
41.78M company shares as of Aug 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Suvretta Capital Management, LLCInstitution | 9.98% | 4.17M | 13Fas of Jun 30, 2026 |
FMR LLCInstitution | 7.67% | 3.20M | 13Fas of Jun 30, 2026 |
Sr One Capital Management, LPInstitution | 5.75% | 2.40M | 13Fas of Jun 30, 2026 |
Deep Track Capital, LPInstitution | 4.79% | 2.00M | 13Fas of Jun 30, 2026 |
Citadel Advisors LLCInstitution | 4.49% | 1.88M | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- Hims & Hers Health
Dominant US telehealth platform prescribing compounded oral minoxidil at scale
- Kenvue
Owns Rogaine®, the #1 OTC topical minoxidil brand globally
- Eli Lilly
Global pharma with the only FDA-approved oral systemic for alopecia areata
- Pfizer
Global pharma with Litfulo, the first oral JAK inhibitor approved for severe AA
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Veradermics | $99.29 | +0.85% | $4.11B | — | — | — | — |
| Hims & Hers Health | $28.79 | +0.45% | $6.40B | — | 109.9 | 2.5 | +38.3% |
| Kenvue | $19.07 | −0.28% | $36.73B | 22.0 | 16.0 | 2.4 | +3.0% |
| Eli Lilly | $1,160.08 | +0.06% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Pfizer | $28.99 | −0.14% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Median | 38.3 | 22.2 | 2.5 | +20.6% |